Fisher & Paykel Healthcare (NZSE:FPH) Margin Surge To 20.2% Tests Premium Valuation Narrative

Simply Wall St.

05/27

Fisher & Paykel Healthcare (NZSE:FPH) has opened FY 2026 with first half revenue of NZ$1.1b and basic EPS of NZ$0.36, setting the tone for investors focused on how its profit engine is tracking. The ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2638544741"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638544741\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638544741?lang=zh_CN&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/875015-main-header/1585186825715","is_english":true,"pubTime":"2026-05-27 01:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638544741","market":"nz","top_or_hot":-1,"title":"Fisher & Paykel Healthcare (NZSE:FPH) Margin Surge To 20.2% Tests Premium Valuation Narrative","media":"Simply Wall St.","content":"<div>\n<p>Fisher & Paykel Healthcare (NZSE:FPH) has opened FY 2026 with first half revenue of NZ$1.1b and basic EPS of NZ$0.36, setting the tone for investors focused on how its profit engine is tracking. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/fisher-paykel-healthcare-nzsefph-margin-surge-to-202-tests-p\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fisher & Paykel Healthcare (NZSE:FPH) Margin Surge To 20.2% Tests Premium Valuation Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFisher & Paykel Healthcare (NZSE:FPH) Margin Surge To 20.2% Tests Premium Valuation Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-27 01:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/fisher-paykel-healthcare-nzsefph-margin-surge-to-202-tests-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fisher & Paykel Healthcare (NZSE:FPH) has opened FY 2026 with first half revenue of NZ$1.1b and basic EPS of NZ$0.36, setting the tone for investors focused on how its profit engine is tracking. The ...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/fisher-paykel-healthcare-nzsefph-margin-surge-to-202-tests-p\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/fisher-paykel-healthcare-nzsefph-margin-surge-to-202-tests-p","article_id":"2638544741","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/875015-main-header/1585186825715"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/fisher-paykel-healthcare-nzsefph-margin-surge-to-202-tests-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2638544741","pubTimestamp":1779815834,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Fisher & Paykel Healthcare (NZSE:FPH) has opened FY 2026 with first half revenue of NZ$1.1b and basic EPS of NZ$0.36, setting the tone for investors focused on how its profit engine is tracking. The company has seen revenue move from NZ$951.2m and EPS of NZ$0.26 in the first half of FY 2025 to NZ$1.1b and EPS of NZ$0.36 in the latest half, with trailing 12 month EPS reaching NZ$0.80 alongside a net profit margin of 20.2% versus 9.4% a year earlier. This puts profitability firmly in focus as...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","FPH":"五点控股","BK4585":"ETF&股票定投概念","BK4193":"多样化房地产活动","BK8004":"医疗保健设备","XLV":"健康照护类股ETF-SPDR","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","LABU":"三倍做多标普生物-Direxion","FPH.NZ":"Fisher & Paykel Healthcare Corporation Limited Ord Shares"},"translate_title":"斐雪派克医疗保健(NZSE：FPH)利润率飙升至20.2%考验溢价估值叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FPH":1.5,"XLV":1.5,"XBI":0.6,"FPH.NZ":1.5,"LABU":0.6},"content_text":"Fisher & Paykel Healthcare (NZSE:FPH) has opened FY 2026 with first half revenue of NZ$1.1b and basic EPS of NZ$0.36, setting the tone for investors focused on how its profit engine is tracking. The company has seen revenue move from NZ$951.2m and EPS of NZ$0.26 in the first half of FY 2025 to NZ$1.1b and EPS of NZ$0.36 in the latest half, with trailing 12 month EPS reaching NZ$0.80 alongside a net profit margin of 20.2% versus 9.4% a year earlier. This puts profitability firmly in focus as you weigh the earnings outlook and margin profile. See our full analysis for Fisher & Paykel Healthcare. With the latest numbers on the table, the next step is to set these profit and margin trends against the prevailing market narratives to see which views are supported and which may need a rethink. See what the community is saying about Fisher & Paykel Healthcare NZSE:FPH Earnings & Revenue History as at May 2026 AdvertisementMargins Step Up To 20.2%  On a trailing 12 month basis, net profit margin sits at 20.2% compared with 9.4% a year earlier, alongside trailing revenue of NZ$2.3b and net income of NZ$468.5m. Bulls point out that this 20.2% margin and 144.8% trailing earnings growth line up with management talking about a 63% gross margin and thousands of efficiency projects, yet:\n     R&D running at about 10% of revenue and capital spend of roughly NZ$210m are being funded from a balance sheet that carries NZ$237.8m of net cash, which supports the bullish idea of capacity to keep investing while margins hold. At the same time, tariffs currently reduce gross margin by about 1.3 percentage points, so part of the bullish margin story depends on those efficiency gains continuing to offset that drag.    Stronger profitability and the scale of recent margin gains are exactly what bullish investors point to when arguing there is more upside left in the story, even with some cost headwinds still in play. 🐂 Fisher & Paykel Healthcare Bull Case Revenue Growth Outpaces Market  Trailing revenue growth of about 10.7% per year and an earnings growth forecast of around 13.3% per year sit ahead of the NZ market revenue forecast of roughly 3.5% per year according to the provided figures. Consensus narrative highlights product launches like Nova Nasal and Airvo 3 and broader adoption of respiratory therapies as growth drivers, but the reported figures also show:\n     First half FY 2026 revenue of NZ$1,088.5m versus NZ$951.2m in the first half of FY 2025 and NZ$1,069.8m in the second half FY 2025, which lines up with commentary about double digit growth in both hospital and home care segments. Guidance for full year operating revenue of NZ$2.17b to NZ$2.27b and net profit after tax of NZ$410m to NZ$460m, which is consistent with the idea of a larger addressable market but still has to be balanced against longer term five year earnings that declined about 12% per year.    Premium P/E And DCF Gap  The stock trades on a trailing P/E of 49.4x, above the peer average of 42.2x and the global medical equipment industry at 25.4x, while the current share price of NZ$36.73 sits above the DCF fair value of NZ$33.34. Bears argue that with five year earnings having declined about 12% per year and a DCF figure below the share price, the premium valuation leaves little room for disappointment, and the numbers show:\n     Even with trailing earnings up 144.8%, the P/E multiple remains higher than both peers and the wider industry, which supports the bearish concern that expectations are already demanding. The difference between the NZ$36.73 share price and the NZ$33.34 DCF fair value, alongside an analyst price target of NZ$39.60, underlines how tightly the current price is anchored to optimistic growth assumptions rather than the cash flow estimate alone.    If you are weighing whether this premium is justified by future growth or leans too far ahead of fundamentals, it helps to line up these valuation markers with your own expectations for margins and demand. 🐻 Fisher & Paykel Healthcare Bear Case Next Steps To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Fisher & Paykel Healthcare on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves. With bulls and bears both making strong points, it makes sense to look through the underlying figures yourself and see which narrative you lean toward. If you want a shortcut to the upbeat angles already flagged by the data, start by reviewing the 2 key rewards See What Else Is Out There Fisher & Paykel Healthcare carries a premium P/E above peers and a share price above the stated DCF fair value, which together leave limited room for disappointment. If you are uneasy about paying up for that kind of pricing power, it is worth comparing against companies screened as 212 high quality undervalued stocks to see where expectations and price look better aligned.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}